WHO: Spread Of Drug-resistant Superbugs Surging

A researcher separates pupae from Aedes aegypti mosquitoes carrying Wolbachia, a dengue-blocking bacteria, at the Oxitec facility during a press tour, in Campinas, Sao Paulo state, Wednesday, Oct. 1, 2025. (AP Photo/Ettore Chiereguini)
A researcher separates pupae from Aedes aegypti mosquitoes carrying Wolbachia, a dengue-blocking bacteria, at the Oxitec facility during a press tour, in Campinas, Sao Paulo state, Wednesday, Oct. 1, 2025. (AP Photo/Ettore Chiereguini)
TT

WHO: Spread Of Drug-resistant Superbugs Surging

A researcher separates pupae from Aedes aegypti mosquitoes carrying Wolbachia, a dengue-blocking bacteria, at the Oxitec facility during a press tour, in Campinas, Sao Paulo state, Wednesday, Oct. 1, 2025. (AP Photo/Ettore Chiereguini)
A researcher separates pupae from Aedes aegypti mosquitoes carrying Wolbachia, a dengue-blocking bacteria, at the Oxitec facility during a press tour, in Campinas, Sao Paulo state, Wednesday, Oct. 1, 2025. (AP Photo/Ettore Chiereguini)

The World Health Organization sounded the alarm Monday over soaring numbers of drug-resistant bacterial infections, compromising the effectiveness of life-saving treatments and rendering minor injuries and common infections potentially deadly.

The United Nations' health agency warned that one in six laboratory-confirmed bacterial infections worldwide in 2023 showed resistance to antibiotic treatments, AFP reported.

"These findings are deeply concerning," Yvan J-F. Hutin, head of the WHO's antimicrobial resistance department, told reporters.

"As antibiotic resistance continues to rise, we're running out of treatment options and we're putting lives at risk."

Bacteria have long developed resistance against medicines designed to fight them, rendering many drugs useless.

This has been accelerated by the massive use of antibiotics to treat humans, animals and food.

Antimicrobial-resistant (AMR) superbugs directly cause over a million deaths and contribute to nearly five million deaths every year, according to the WHO.

In a report on AMR surveillance, the WHO examined resistance prevalence estimates across 22 antibiotics used to treat infections of the urinary and gastrointestinal tracts, the bloodstream and those used to treat gonorrhea.

In the five years leading to up 2023, antibiotic resistance increased in over 40 percent of the monitored antibiotics, with an average annual rise of between five and 15 percent, the report found.

For urinary tract infections, resistance to commonly-used antibiotics was typically higher than 30 percent globally, it showed.

The report looked at eight common bacteria pathogens, including E. coli and K. pneumoniae, which can lead to severe bloodstream infections that frequently result in sepsis, organ failure and death.

The WHO warned that more than 40 percent of E. coli infections and 55 percent of K. pneumoniae infections globally are now resistant to third-generation cephalosporins -- the first-choice treatment for these infections.

"Antimicrobial resistance is outpacing advances in modern medicine, threatening the health of families worldwide," WHO chief Tedros Adhanom Ghebreyesus warned in a statement.

The WHO hailed improvements in surveillance, but warned that 48 percent of countries were still not reporting any AMR data.

"We are definitely flying blind in a number of countries and regions that have insufficient surveillance systems for antimicrobial resistance," Hutin acknowledged.

Judging from the available data, most resistance was found in places with weaker health systems and less surveillance, WHO said.

The highest resistance was found in the Southeast Asian and Eastern Mediterranean regions, where one in three reported infections were resistant.

In the African region, one in five infections was meanwhile resistant.

Silvia Bertagnolio, who heads the WHO unit for antimicrobial resistance surveillance, told reporters it was unsurprising that resistance would be higher in places with weaker health systems, since they may lack the capacity to diagnose or treat pathogens effectively.

The differences could also be linked to the fact that countries with less surveillance may test and provide data on fewer patients and only those with the most serious infections, she said.

WHO has warned that there are not enough new tests and treatments in the pipeline to tackle the growing spread of drug-resistant bacteria.

This is creating a significant "future threat", Hutin cautioned.

"The increasing antibiotic use, the increasing resistance and the reduction of the pipeline is a very dangerous combination."



Study Questions Melatonin Use and Heart Health but Don't Lose Sleep Over it

FILE - The label for a bottle of melatonin pills is seen in New York on Thursday, June 2, 2022. (AP Photo/Patrick Sison, File)
FILE - The label for a bottle of melatonin pills is seen in New York on Thursday, June 2, 2022. (AP Photo/Patrick Sison, File)
TT

Study Questions Melatonin Use and Heart Health but Don't Lose Sleep Over it

FILE - The label for a bottle of melatonin pills is seen in New York on Thursday, June 2, 2022. (AP Photo/Patrick Sison, File)
FILE - The label for a bottle of melatonin pills is seen in New York on Thursday, June 2, 2022. (AP Photo/Patrick Sison, File)

Don’t lose sleep over headlines linking melatonin to heart failure.

That’s the message after some scary-sounding reports about a preliminary study involving the sleep-related supplement. It raised questions about the safety of long term use of melatonin for insomnia.

Doctors have long known that too little or interrupted sleep raises the risk of heart disease. But heart experts say this kind of so-called observational study can't prove that melatonin use plays any role — instead of the insomnia patients were trying to treat.

“We should not raise the alarm and tell patients to stop taking all their melatonin,” said Dr. Pratik Sandesara, an interventional cardiologist at Emory Healthcare who wasn’t involved with the research.

Our bodies naturally produce melatonin, a hormone that regulates our sleep cycles. Levels normally increase as it gets darker in the evening, triggering drowsiness.

People may take lab-produced melatonin to help them fall asleep or to adjust for jet lag or time changes.

The new study used international electronic health records, tracking adults diagnosed with insomnia who had a melatonin prescription that suggested they used the supplement for at least a year.

Over five years, 4.6% of the chronic melatonin users developed heart failure compared to 2.7% of insomnia patients whose charts showed no melatonin use, the researchers found. The study is being presented at an American Heart Association meeting but hasn’t undergone peer review.

But only certain countries require a melatonin prescription. It’s over-the-counter in the US, meaning Americans in the study might have used the supplements without it being recorded, said Northwestern University cardiology chief Dr. Clyde Yancy, who wasn't involved in the study. The study also did not show dosages, The Associated Press reported.

Also, US supplements don’t require government approval, meaning brands can vary in their ingredients. The researchers, from SUNY Downstate Health Sciences University, characterized the findings as a call for more research.

Meanwhile, patients wondering about melatonin should talk it over with their doctors, said Emory’s Sandesara. Generally doctors recommend it for short-term use, like for jet lag.

Yancy noted that while the study doesn't prove there's a danger from long term melatonin use, there's also no evidence that people should use melatonin indefinitely.

And one key to better shut-eye is to practice better sleep hygiene, like making sure your room is dark.

“When we expose ourselves to blue light in particular at night, we are diminishing our melatonin levels. That’s science,” he said. Sleep problems aren’t about “just being sleepy and tired — they’re putting yourself at risk.”


Prince Harry Apologizes to Canada Over Hat

Prince Harry (right) and Meghan Markle sit during the eight inning between the Toronto Blue Jays and the Los Angeles Dodgers during Game 4 of the 2025 MLB World Series at Dodger Stadium (Shutterstock)
Prince Harry (right) and Meghan Markle sit during the eight inning between the Toronto Blue Jays and the Los Angeles Dodgers during Game 4 of the 2025 MLB World Series at Dodger Stadium (Shutterstock)
TT

Prince Harry Apologizes to Canada Over Hat

Prince Harry (right) and Meghan Markle sit during the eight inning between the Toronto Blue Jays and the Los Angeles Dodgers during Game 4 of the 2025 MLB World Series at Dodger Stadium (Shutterstock)
Prince Harry (right) and Meghan Markle sit during the eight inning between the Toronto Blue Jays and the Los Angeles Dodgers during Game 4 of the 2025 MLB World Series at Dodger Stadium (Shutterstock)

The Duke of Sussex has apologized to Canada for wearing a Los Angeles Dodgers hat while attending a World Series game against the Toronto Blue Jays.

Prince Harry joked that he was “under duress” when he wore the bright blue cap during the epic Game 4 of the World Series in Los Angeles.

He thought it was “the polite thing to do” after being invited to the game by the Dodgers' owner.

According to BBC, his headgear choice upset many in Canada - a Commonwealth nation- who criticized him for not showing his allegiance to the realm, or to the only Canadian team in Major League Baseball.

Prince Harry's father King Charles is the head of state of Canada and of 13 other Commonwealth realms.

“Firstly, I would like to apologize to Canada for wearing it,” he said in a CTV interview. “Secondly, I was under duress. There wasn't much choice.”

The prince - wearing a Blue Jays hat during the interview - quipped that “when you're missing a lot of hair on top, and you're sitting under flood lights, you'll take any hat that's available.”

He plans to wear a Blue Jays hat from now on and rooted for the Toronto team in subsequent games, appearing to do so in a clip posted on social media by the Duchess of Sussex - a Los Angeles native - when the Dodgers won the series in Game 7 a few days later.

Prince Harry, who was given a Blue Jays hat while meeting with Canada's oldest veterans for a Remembrance event on Thursday, also said that admitting that he is a Toronto fan would likely make his reception in California more difficult.

The prince and his wife, a former actress who lived in Canada while filming her TV drama Suits, moved to California after stepping back as full-time royals in 2020.

The couple's presence in the Chavez Ravine-set stadium in Los Angeles also disgruntled many Dodgers fans in the US.

They took to social media to voice their upset over the couple's plum front-row seats during the 18-inning game, while local legends such as Magic Johnson and former pitcher Dodgers Sandy Koufax were seated behind them.


Gilead's Breast Cancer Drug Fails to Meet Main Goal of Late-stage Study

Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
TT

Gilead's Breast Cancer Drug Fails to Meet Main Goal of Late-stage Study

Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo

Gilead Sciences said on Friday its breast cancer drug Trodelvy did not significantly lower the risk of disease progression in patients when used as a first-line treatment, failing to meet the main goal of a late-stage study, Reuters reported.

Gilead said an early trend for extending overall survival, a key measure of treatment efficacy, was observed favoring patients treated with Trodelvy, compared to chemotherapy.

The data for overall survival, however, was not mature at the time of the primary analysis, the company said, adding that the study will continue to assess this secondary goal.

Trodelvy was being tested in patients with HR+/HER2-negative metastatic breast cancer, the most common subtype of the cancer, as a first-line treatment following hormone therapy.